Brano Therapeutics is a Singapore-based biotech developing oral small-molecule therapies for cardiometabolic heart failure with preserved ejection fraction (HFpEF). Built on translational science from Duke-NUS, Brano targets a disease-relevant metabolic root associated with cardiac metabolic stress and dysfunction in HFpEF. The company is advancing proprietary compounds to restore cardiac metabolic flexibility and improving disease biology in a large, underserved heart failure population.